Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 328

1.

B cells as therapeutic targets for rheumatic diseases.

Looney RJ, Anolik J, Sanz I.

Curr Opin Rheumatol. 2004 May;16(3):180-5. Review.

PMID:
15103242
2.

B-cell-targeted therapy for systemic lupus erythematosus.

Sabahi R, Anolik JH.

Drugs. 2006;66(15):1933-48.

PMID:
17100405
3.

Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases.

Chambers SA, Isenberg D.

Lupus. 2005;14(3):210-4. Review.

PMID:
15807198
4.

Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future.

Sfikakis PP, Boletis JN, Tsokos GC.

Curr Opin Rheumatol. 2005 Sep;17(5):550-7. Review.

PMID:
16093832
5.

B cell targeted therapies in autoimmune diseases.

Isenberg DA.

J Rheumatol Suppl. 2006 May;77:24-8. Review.

PMID:
16652442
6.

B-cell depletion for rheumatic diseases: where are we?

Cohen SB.

MedGenMed. 2005 Jun 8;7(2):72. Review.

7.

[B cell targeting therapy using the anti-CD20 antibody in autoimmune diseases].

Tanaka Y.

Yakugaku Zasshi. 2009 Jun;129(6):675-9. Review. Japanese.

8.

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.

Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC; REFLEX Trial Group.

Arthritis Rheum. 2006 Sep;54(9):2793-806.

9.

B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus.

Eisenberg R, Albert D.

Nat Clin Pract Rheumatol. 2006 Jan;2(1):20-7. Review.

PMID:
16932648
10.

[Interleukin 10 in disseminated lupus erythematosus].

Emilie D.

J Soc Biol. 2002;196(1):19-21. Review. French.

PMID:
12134628
11.
12.

B cell depletion therapy in rheumatic disease.

Edwards JC, Cambridge G, Leandro MJ.

Best Pract Res Clin Rheumatol. 2006 Oct;20(5):915-28. Review.

PMID:
16980214
13.

Monoclonal antibodies in the treatment of systemic lupus erythematosus.

Robak E, Robak T.

Curr Drug Targets. 2009 Jan;10(1):26-37. Review.

PMID:
19149533
14.

Biologics in the treatment of systemic lupus erythematosus.

Lateef A, Petri M.

Curr Opin Rheumatol. 2010 Sep;22(5):504-9. doi: 10.1097/BOR.0b013e32833b475e. Review.

PMID:
20502332
15.

New treatments for SLE: cell-depleting and anti-cytokine therapies.

Anolik JH, Aringer M.

Best Pract Res Clin Rheumatol. 2005 Oct;19(5):859-78. Review.

PMID:
16150407
16.

B cell depletion therapy in systemic rheumatic diseases: different strokes for different folks?

Stohl W, Looney RJ.

Clin Immunol. 2006 Oct;121(1):1-12. Epub 2006 May 11. Review.

PMID:
16697258
17.

Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy.

Treon SP, Shima Y, Preffer FI, Doss DS, Ellman L, Schlossman RL, Grossbard ML, Belch AR, Pilarski LM, Anderson KC.

Semin Oncol. 1999 Oct;26(5 Suppl 14):97-106.

PMID:
10561024
18.

B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.

Harvey PR, Gordon C.

BioDrugs. 2013 Apr;27(2):85-95. doi: 10.1007/s40259-013-0015-8.

PMID:
23456653
19.

[Novel B-cell directed strategies for the treatment of rheumatic diseases].

Tarner IH.

Z Rheumatol. 2009 Jul;68(5):380-9. doi: 10.1007/s00393-009-0438-2. Review. German.

PMID:
19513729
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk